Lexaria Bioscience (LEXX) Total Liabilities (2010 - 2026)

Lexaria Bioscience has disclosed Total Liabilities across 17 years of filings, most recently posting $276997.0 for Q1 2026.

• Total Liabilities for Q1 2026 came in at $276997.0, down 85.55% year-over-year; the trailing twelve-month figure through Feb 2026 was $276997.0 (down 85.55% YoY), and the FY2025 annual result was $1.6 million, up 30.08% from the prior year.
• Total Liabilities came in at $276997.0 for Q1 2026 at Lexaria Bioscience, down from $1.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $1.9 million in Q1 2025 to a low of $194623.0 in Q1 2022.
• The 5-year median for Total Liabilities is $281520.0 (2022), against an average of $702041.9.
• Across the five-year window, Total Liabilities jumped 838.67% in 2025 and sank 85.55% in 2026, its largest moves.
• Lexaria Bioscience's Total Liabilities stood at $281520.0 in 2022, then slipped by 9.76% to $254040.0 in 2023, then jumped by 57.34% to $399718.0 in 2024, then soared by 282.11% to $1.5 million in 2025, then slumped by 81.86% to $276997.0 in 2026.
• The last three Total Liabilities figures came in at $276997.0 (Q1 2026), $1.5 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.